TuHURA Biosciences, Inc.

NASDAQ:HURA

Biotechnology

Healthcare
$1.36 +6.37%

+$0.14 today

Market cap
$89.43M
Beta
0.01
P/E (TTM)
-4.6
EPS (TTM)
-$0.52
52W Low $0.41High $3.90

Volume 0.20M

Average 0.85M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$27.63M

FY 2025 · Annual

Investing Cash Flow

-$1.34M

FY 2025 · Annual

Financing Cash Flow

$19.93M

FY 2025 · Annual

-33.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(7.02M)(9.37M)(29.32M)(21.68M)(30.05M)
Depreciation & Amortization380.69K373.09K177.38K116.71K71.27K
Deferred Income Tax00000
Stock-Based Compensation654.53K218.28K478.89K1.96M6.42M
Change in Working Capital(55K)1.56M486.92K3.29M(3.15M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital(55K)1.56M486.92K3.29M(3.15M)
Other Non-Cash Items(527.06K)(294.07K)21M1.59M(924.51K)
Operating Cash Flow(6.56M)(7.51M)(11.95M)(14.73M)(27.63M)
Capital Expenditures(3.28K)(232K)(79.22K)(57.91K)(76.08K)
Acquisitions (Net)00(1.22M)(5.99M)(1.26M)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.28K)(36.28K)(1.3M)(6.05M)(1.34M)
Debt Repayment294.07K(350K)2.69M28.57M616.98K
Common Stock Issued5.6M1.9M10.58M5M21.92M
Common Stock Repurchased00(24.75K)00
Dividends Paid(8K)(8K)(6K)0(8.36K)
Other Financing Activities8K00(3.8M)(2.61M)
Financing Cash Flow7.04M16.25M2.66M29.77M19.93M
Effect of Forex Changes00000
Net Change in Cash477.91K8.71M(10.59M)8.99M(9.04M)
Free Cash Flow(6.57M)(7.54M)(12.03M)(14.79M)(27.71M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$30.1M
+ D&A$71.3K
+ Stock-Based Comp$6.4M
+ Deferred Tax$0
- Working Capital-$3.1M
- Other Non-Cash-$924.5K
= Operating Cash Flow-$27.6M
- Capex-$76.1K
= Free Cash Flow-$27.7M

Analysis

FY2025 free cash flow is -$27.7M. FCF conversion is 92.2% of net income. Operating cash flow was -$27.6M, with capex of -$76.1K. The largest bridge item is Stock-Based Comp at $6.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 13, 2026
10-QQuarterly reportNov 13, 2026
8-KCurrent reportNov 6, 2026
8-KCurrent reportOct 16, 2026
8-KCurrent reportSep 24, 2026

Does HURA generate free cash flow?

TuHURA Biosciences, Inc. (HURA) generated -$27.71M of free cash flow in fiscal 2025.

How much operating cash flow does HURA produce?

Operating cash flow was -$27.63M, before capital expenditures of $76,083.00.